Summit Therapeutics VP Corporate Controller & PAO Jeffrey Maranian resigns effective Jan 21, 2022
Summit Therapeutics Inc.
Jeffrey Maranian resigned as VP Corporate Controller and Principal Accounting Officer effective Jan 21, 2022; personal decision, no disagreement with the company.
Company plans to search for a successor for both VP Corporate Controller and Principal Accounting Officer positions.
Maranian will assist with transition under a short-term consulting agreement.
On January 7, 2022, Jeffrey Maranian notified Summit Therapeutics Inc. (the “Company”) that he was resigning from his positions as VP Corporate Controller and Principal Accounting Officer of the Company, effective as of close of business on January 21, 2022.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Jeffrey Maranian resigned as VP Corporate Controller and Principal Accounting Officer at Summit Therapeutics Inc..
Action
resigned
Role
VP Corporate Controller and Principal Accounting Officer
Exact text from the filing
On January 7, 2022, Jeffrey Maranian notified Summit Therapeutics Inc. (the “Company”) that he was resigning from his positions as VP Corporate Controller and Principal Accounting Officer of the Company, effective as of close of business on January 21, 2022.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.